Colorectal Cancer
Conditions
Keywords
CRC, Metastatic CRC, APO2L/TRAIL
Brief summary
This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab (only for Cohort 6 subjects who have not received prior bevacizumab therapy).
Interventions
DRUGFOLFIRI regimen
Intravenous repeating dose
DRUGbevacizumab
Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
DRUGcetuximab
Intravenous repeating dose
DRUGdulanermin
Intravenous repeating dose
DRUGirinotecan
Intravenous repeating dose
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed Informed Consent Form * Age \>= 18 years * Histologically confirmed CRC with evidence of metastases and measurable tumor lesion(s) * Progression of disease following, or intolerance to, treatment with 5-fluorouracil-based therapy * Progression of disease during or within =\< 6 months following the last dose of a prior first-line treatment with a fluoropyrimidine and oxaliplatin-based chemotherapy plus bevacizumab for metastatic disease * Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential (use per institutional standard) * Life expectancy of \> 3 months * Willingness and capability to be accessible for study follow-up
Exclusion criteria
* Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response * Radiation therapy to a peripheral lesion within 14 days prior to Day 1; Radiation therapy to a thoracic, abdominal or pelvic field within 28 days prior to Day 1 * Chemotherapy, hormonal therapy, or immunology within 4 weeks prior to Day 1 * Previous exposure to DR4-targeted therapy or DR5-targeted therapy * Evidence of clinically detectable ascites on Day * Other invasive malignancies within 5 years prior to Day 1 (other than basal cell carcinoma of the skin or in situ carcinoma of the cervix) * History or evidence upon physical examination of CNS disease * Active infection requiring parenteral antibiotics on Day 1 * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study and fine needle aspirations within 7 days prior to Day 1 * Pregnancy or lactation * Serious nonhealing wound, ulcer, or bone fracture * Current or recent participation in another experimental drug study * Clinically significant cardiovascular disease * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications * Cohort 5 only: Subjects who have a Kras mutation will be excluded from enrollment * The following
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety and tolerability of dulanermin administered in combination with Camptosar and Erbitux | Length of study |
| The safety and tolerability of dulanermin administered in combination with FOLFIRI (with or without Bevacizumab) | Length of study |
Countries
United States
Outcome results
None listed